Stock BRPA NRX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

NRx Pharmaceuticals, Inc. Stock

Equities

BRPA

US6294442099

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
3.54 USD +12.74% Intraday chart for NRx Pharmaceuticals, Inc. +16.45% -23.04%
04-18 NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq MT
04-18 Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches MT

Financials

Sales 2024 * - Sales 2025 * - Capitalization 36.89M 50.43M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.59%
More Fundamentals * Assessed data

Chart NRx Pharmaceuticals, Inc.

Dynamic Chart

Latest news about NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches MT
Top Premarket Decliners MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital MT
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics CI
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) CI
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression CI
Transcript : NRx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Apr 01, 2024
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call
NRx Pharmaceuticals, Inc., Conversio Health, LLC and Nephron Pharmaceuticals Corporation Complete Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) CI
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression CI
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression CI
NRx Pharmaceuticals Gets Fast-Track Designation for NRX-101 UTI Treatment DJ
More news

Latest transcript on NRx Pharmaceuticals, Inc.

Logo NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Apr 01, 2024
More transcripts

Analyst Recommendations on NRx Pharmaceuticals, Inc.

Ascendiant Capital Starts NRX Pharmaceuticals at Buy With $4 Price Target MT
HC Wainwright Starts NRX Pharmaceuticals at Buy With $2 Price Target MT
More recommendations

Press releases NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock AQ
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement AQ
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100 AQ
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression AQ
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update AQ
More press releases

News in other languages on NRx Pharmaceuticals, Inc.

Relief Therapeutics a creusé sa perte nette en 2022
Bourse Zurich: dans le rouge, le SMI finit sous les 10'700 points
Relief et NRX finalisent le règlement de leur litige sur l'aviptadil
Relief und NRx unterzeichnen endgültige Vergleichsvereinbarungen
Relief Therapeutics promeut son trésorier directeur général
More news

Quotes and Performance

1 day+12.74%
1 week+16.45%
Current month-24.98%
1 month-31.40%
3 months-7.38%
6 months+26.43%
Current year-23.04%
More quotes

Highs and lows

1 week
2.72
Extreme 2.7201
3.64
1 month
2.72
Extreme 2.7201
6.00
Current year
2.72
Extreme 2.7201
7.33
1 year
2.21
Extreme 2.21
12.00
3 years
2.21
Extreme 2.21
488.00
5 years
2.21
Extreme 2.21
769.90
10 years
2.21
Extreme 2.21
769.90
More quotes

Managers and Directors - NRx Pharmaceuticals, Inc.

Managers TitleAgeSince
Stephen Willard CEO
 Chief Executive Officer 63 22-07-11
Jonathan Javitt FOU
 Founder 67 17-09-17
Richard Narido DFI
 Director of Finance/CFO 46 23-09-12
Members of the board TitleAgeSince
Jonathan Javitt FOU
 Founder 67 17-09-17
Stephen Willard CEO
 Chief Executive Officer 63 22-07-11
Janet Rehnquist BRD
 Director/Board Member - 12-26
More insiders

Quotes

Date Price Change Volume
24-04-26 3.54 +12.74% 280,114
24-04-25 3.14 +0.64% 102,032
24-04-24 3.12 +2.30% 97,946
24-04-23 3.05 +1.67% 106,468
24-04-22 3 -1.32% 211,625

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Sector
Biotechnology & Medical Research
Calendar
2024-05-13 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.54 USD
Average target price
37.5 USD
Spread / Average Target
+959.32%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NRX PHARMACEUTICALS, INC. Stock NRx Pharmaceuticals, Inc.
-23.04% 36.89M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BRPA Stock